vs
Side-by-side financial comparison of Claritev Corp (CTEV) and USANA HEALTH SCIENCES INC (USNA). Click either name above to swap in a different company.
USANA HEALTH SCIENCES INC is the larger business by last-quarter revenue ($250.2M vs $246.6M, roughly 1.0× Claritev Corp). USANA HEALTH SCIENCES INC runs the higher net margin — 3.0% vs -32.7%, a 35.7% gap on every dollar of revenue. On growth, Claritev Corp posted the faster year-over-year revenue change (6.2% vs -3.0%). Over the past eight quarters, USANA HEALTH SCIENCES INC's revenue compounded faster (11.8% CAGR vs 2.5%).
Usana Health Sciences, Inc., or USANA, is an American multi-level marketing company based in Salt Lake City, Utah. As of 2021, Usana was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 24 countries via a network of independent distributors.
CTEV vs USNA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $250.2M |
| Net Profit | $-80.6M | $7.5M |
| Gross Margin | — | 76.2% |
| Operating Margin | -3.1% | 5.5% |
| Net Margin | -32.7% | 3.0% |
| Revenue YoY | 6.2% | -3.0% |
| Net Profit YoY | 41.6% | -20.0% |
| EPS (diluted) | $-4.88 | $0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $250.2M | ||
| Q4 25 | $246.6M | $226.2M | ||
| Q3 25 | $246.0M | $213.7M | ||
| Q2 25 | $241.6M | $235.8M | ||
| Q1 25 | $231.3M | $249.5M | ||
| Q4 24 | $232.1M | $213.6M | ||
| Q3 24 | $230.5M | $200.2M | ||
| Q2 24 | $233.5M | — |
| Q1 26 | — | $7.5M | ||
| Q4 25 | $-80.6M | $180.0K | ||
| Q3 25 | $-69.8M | $-6.5M | ||
| Q2 25 | $-62.6M | $9.7M | ||
| Q1 25 | $-71.3M | $9.4M | ||
| Q4 24 | $-138.0M | $4.5M | ||
| Q3 24 | $-391.4M | $10.6M | ||
| Q2 24 | $-576.7M | — |
| Q1 26 | — | 76.2% | ||
| Q4 25 | — | 78.2% | ||
| Q3 25 | — | 77.2% | ||
| Q2 25 | — | 78.7% | ||
| Q1 25 | — | 79.0% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | — | 80.4% | ||
| Q2 24 | — | — |
| Q1 26 | — | 5.5% | ||
| Q4 25 | -3.1% | 1.7% | ||
| Q3 25 | 4.1% | 0.6% | ||
| Q2 25 | 6.9% | 7.1% | ||
| Q1 25 | 4.2% | 6.3% | ||
| Q4 24 | -17.8% | 3.8% | ||
| Q3 24 | -146.7% | 7.8% | ||
| Q2 24 | -224.4% | — |
| Q1 26 | — | 3.0% | ||
| Q4 25 | -32.7% | 0.1% | ||
| Q3 25 | -28.4% | -3.1% | ||
| Q2 25 | -25.9% | 4.1% | ||
| Q1 25 | -30.8% | 3.8% | ||
| Q4 24 | -59.4% | 2.1% | ||
| Q3 24 | -169.8% | 5.3% | ||
| Q2 24 | -247.0% | — |
| Q1 26 | — | $0.41 | ||
| Q4 25 | $-4.88 | $-0.10 | ||
| Q3 25 | $-4.23 | $-0.36 | ||
| Q2 25 | $-3.81 | $0.52 | ||
| Q1 25 | $-4.38 | $0.49 | ||
| Q4 24 | $-8.49 | $0.23 | ||
| Q3 24 | $-24.25 | $0.56 | ||
| Q2 24 | $-35.78 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $162.8M |
| Total DebtLower is stronger | $4.6B | — |
| Stockholders' EquityBook value | $-173.9M | — |
| Total Assets | $4.9B | $739.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $162.8M | ||
| Q4 25 | $16.8M | $158.4M | ||
| Q3 25 | $39.2M | $145.3M | ||
| Q2 25 | $56.4M | $151.3M | ||
| Q1 25 | $23.1M | $179.6M | ||
| Q4 24 | $16.8M | $181.8M | ||
| Q3 24 | $86.6M | $364.9M | ||
| Q2 24 | $48.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — |
| Q1 26 | — | — | ||
| Q4 25 | $-173.9M | — | ||
| Q3 25 | $-101.8M | $528.1M | ||
| Q2 25 | $-39.9M | $531.1M | ||
| Q1 25 | $14.8M | $529.8M | ||
| Q4 24 | $84.0M | $532.1M | ||
| Q3 24 | $207.6M | $533.1M | ||
| Q2 24 | $603.4M | — |
| Q1 26 | — | $739.0M | ||
| Q4 25 | $4.9B | $742.9M | ||
| Q3 25 | $5.0B | $726.6M | ||
| Q2 25 | $5.1B | $734.5M | ||
| Q1 25 | $5.1B | $746.6M | ||
| Q4 24 | $5.2B | $748.2M | ||
| Q3 24 | $5.3B | $671.3M | ||
| Q2 24 | $5.7B | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 304.87× | — | ||
| Q4 24 | 53.67× | — | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | — |
| Free Cash FlowOCF − Capex | $36.4M | — |
| FCF MarginFCF / Revenue | 14.8% | — |
| Capex IntensityCapex / Revenue | 12.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $66.3M | — | ||
| Q3 25 | $19.9M | $-2.0M | ||
| Q2 25 | $61.2M | $12.2M | ||
| Q1 25 | $-30.1M | $15.5M | ||
| Q4 24 | $-33.4M | $5.8M | ||
| Q3 24 | $72.8M | $29.5M | ||
| Q2 24 | $18.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | $36.4M | — | ||
| Q3 25 | $-16.3M | $-5.2M | ||
| Q2 25 | $36.6M | $7.2M | ||
| Q1 25 | $-68.9M | $12.7M | ||
| Q4 24 | $-63.8M | $4.0M | ||
| Q3 24 | $41.1M | $27.1M | ||
| Q2 24 | $-7.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 14.8% | — | ||
| Q3 25 | -6.6% | -2.4% | ||
| Q2 25 | 15.2% | 3.0% | ||
| Q1 25 | -29.8% | 5.1% | ||
| Q4 24 | -27.5% | 1.9% | ||
| Q3 24 | 17.8% | 13.6% | ||
| Q2 24 | -3.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 12.1% | — | ||
| Q3 25 | 14.7% | 1.5% | ||
| Q2 25 | 10.2% | 2.1% | ||
| Q1 25 | 16.8% | 1.1% | ||
| Q4 24 | 13.1% | 0.8% | ||
| Q3 24 | 13.8% | 1.2% | ||
| Q2 24 | 10.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.27× | ||
| Q1 25 | — | 1.65× | ||
| Q4 24 | — | 1.29× | ||
| Q3 24 | — | 2.78× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
